1:00PM Agenus announces a reverse stock split of 1:6; effective Oct. 3 (AGEN) 0.55 :
Recent AGEN News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/13/2026 06:59:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 09:04:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 12:52:03 PM
- Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development • Business Wire • 05/11/2026 12:45:00 PM
- Agenus to Provide First Quarter 2026 Financial Report and Corporate Update • Business Wire • 05/04/2026 08:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 08:35:04 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:34:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:02 PM
- アジーナス、BOT+BALアクセスプログラムの独占的グローバルパートナーにBAP Pharmaを指名 • Business Wire • 04/22/2026 03:56:00 PM
- Agenus ernennt BAP Pharma zum exklusiven globalen Partner für die BOT+BAL-Zugangsprogramme • Business Wire • 04/22/2026 12:55:00 AM
- Agenus désigne BAP Pharma comme partenaire mondial exclusif pour les programmes d’accès à la combinaison BOT+BAL • Business Wire • 04/22/2026 12:55:00 AM
- Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 • Business Wire • 04/21/2026 02:00:00 PM
- Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs • Business Wire • 04/21/2026 12:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/20/2026 09:21:47 PM
- Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer • Business Wire • 04/17/2026 08:43:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 08:15:10 PM
- Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 • Business Wire • 04/03/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:29 PM
- アジーナス、MSSまたはpMMRの転移性大腸がんを対象としたBOT+BAL免疫療法併用のグローバル第3相BATTMAN試験で初の患者登録を発表 • Business Wire • 04/02/2026 04:31:00 AM

